iiinova — where your digital self keeps evolving

Another bivalent biologic presented at #EADV2025, this time for #atopicdermatitis #eczema - IL-13 and IL17A/F inhibitor Galvokimig in a small phase IIA RCT potentially very helpful for Asian Th17 AD phenotype or patients at risk of phenotypic switch

020

The third study presented at #EADV2025 from Novartis using spatial transcriptomics to look at #hidradenitis Some beautiful pictures showing the distribution of fibroblasts, B cells, plasma cells, T cells around a lesion IMO more data to suggest a need to hit multiple targets

000

Exciting to hear a new bivalent drug that targets TNF and OX40L Brivekimig for the treatment of #hidradenitis - we likely need more drugs that have multiple targets to treat this difficult disease Looking forward to the explanatory phase III RCTs #EADV2025

000

Probably the closest effort to precision medicine so far in dermatology presented by Michel Gillet - using nanostring measuring gene expression - to differentiate between skin diseases outside of morphology #EADV2025

Zenas Yiu @zznyiu.bsky.social · 18/09/2025

Good and slower burning response from OX-40 inhibitor rocatinlimab for #atopicdermatitis - results from the phase III RCT ROCKET-SHUTTLE which allows concomitant topical steroids #EADV2025

000

Zenas Yiu @zznyiu.bsky.social · 18/09/2025

Really interesting new mechanism of action to target T-regulatory cells in #atopicdermatitis for Rezpeg seems safe and effective in this phase 2b RCT but again this choice of as observed open label extension arm makes it difficult to interpret longer term effect #EADV2025

000

Izokibep shows moderate response, again around 13% delta mark for HiSCR75 at week 12, for #hidradenitis Not convinced more single target biologics are what we need #EADV2025

000

Good to see phase III data for povorcitinib for #hidradenitis. Delta for primary endpoint of HiSCR50 slightly disappointing around 10-12%, but good to see draining tunnels resolving better. Why use as observed imputation for extension, which is biased? #EADV2025

000

Do antibiotics have a direct anti-inflammatory activity in #hidradenitis? Some data to show they do, especially clindamycin, from a 3D seboskin model study from Germany #EADV2025

000

Two interesting spatial transcriptomics studies in #hidradenitis highlighting abnormal epithelialisation and the complex immunological pathogenesis respectively in the EHSF session #EADV2025

000

Zenas Yiu @zznyiu.bsky.social · 08/09/2025

Great to hear the new classification for epidermal differentiation disorders from Edel O’Toole, which follows a logical naming convention starting with the gene. #EADV2025

000

Delighted to have given a plenary on stories of drug discoveries and research in dermatology in my home town of Hong Kong! Thank you to Chester Lai and the GCDS committee for your kind invitation. #GCDS2025 #RxEpi

000

Zenas Yiu @zznyiu.bsky.social · 06/09/2025

Great to hear from Henry Lim in the 1st plenary of the Global Chinese Dermatology Summit that ustekinumab and adalimumab are part of the WHO list of essential medicines! #GCDS2025 #psoriasis

Zenas Yiu @zznyiu.bsky.social · 19/06/2025

We have a great #PhD opportunity with a multi-disciplinary supervisory team to understand the impact of UV radiation on #eczema #atopicdermatitis using methods from epidemiology, wearables, data science, and behavioural science Deadline 7/7/2025! www.findaphd.com/phd...

000

Reposted by Zenas Yiu

Dr. John Cush @rheumnow.bsky.social · 05/06/2025

Target emulation trial w/ data from British Dermatologists Biologics & Immunomodulators Register, studied 231 PSO Rx w/ MTX + Adalimumab against 1553 PSO on ADA. @1Yr MTX did not augment ADA only responses based on Rx survival (79% vs 78%) or PASI75 (49% vs 52%). jamanetwork.com/journals/jam...

jamanetwork.com

011

Zenas Yiu @zznyiu.bsky.social · 24/04/2025

Interested in making a difference for people with #psoriasis in the UK? Apply for this @PsoriasisUK funded PhD with me, Binh Phan, Richard Warren, and Gabriel Rogers and use data from @BADBIR and trials to conduct cost-effectiveness analyses www.findaphd.com/phd...

001

Zenas Yiu @zznyiu.bsky.social · 11/03/2025

Honoured to present on evidence based care in #psoriasis alongside amazing speakers for alopecia areata, urticaria, CTCL, acne, and photoaging at the #AAD2025 yesterday. Learnt a lot from all the speakers on the topics at hand as well as how to get complex messages across

020

Much needed study on new therapies in bullous pemphigoid - more sustained remission for dupilumab after corticosteroid taper #AAD2025

000

Slow and steady response for rocatinlimab, OX40 receptor inhibitor for atopic dermatitis Looks like it is quite targeted and safe in this phase III study - but if the thought is a slower response they probably needed to have a later primary outcome timepoint #AAD2025

Nice to see new therapies coming through for cutaneous lupus erythematosus - phase II data on deucravacitinib for CLE #AAD2025

011

Icotrokinra showing high but slightly lower response rates compared to injectable IL23i for #psoriasis - nonetheless a very high effectiveness for an oral medication #AAD2025

000

Much needed study to look at the impact of dupilumab on itch in epidermolysis bullosa and ichthyosis need a bigger study with a control arm but very promising! #AAD2025

000

ESK-001 showing promise as a targeted inhibitor of TYK2 for psoriasis in a phase II trial - now for the phase III study to confirm findings for blinded primary outcome #AAD2025

Very high negative predictor values presented by Skin Analytics for their DERM AI device in ruling out melanoma I think gold standard for this based on dermatologist diagnosis is still suboptimal and would like longer term data with follow up #AAD2025

000

Nice early results from a small phase IIa trial on Bempikibart, IL7/TSLP inhibitor biologic for alopecia areata in the late breaking session by Brett King Looks like it results in more durable responses compared to JAK inhibitors after treatment cessation #AAD2025

000

Zenas Yiu @zznyiu.bsky.social · 07/03/2025

Fascinating use of AI to increase access to patch testing for allergic contact dermatitis from the Mayo Clinic #AAD2025

000

Second great debate on use of gene expression profiling tests for melanoma and SCC by Emily Chu and David Cotter Definitely need a RCT to be able to say something about cost effectiveness - right population critical

000

Zenas Yiu @zznyiu.bsky.social · 07/03/2025

Really nice start to the 2025 debates session at #AAD2025 by Eugene Semenov and Sharon Wongvibulsin on the advantages, use cases, and limitations of AI in dermatology. Still unclear to me where we can reliably deploy AI in dermatology currently but already widely in use

000

Zenas Yiu @zznyiu.bsky.social · 24/02/2025

Join me at #AAD2025 S065 Great Care for Common Conditions: Combining Evidence and Cost Effectiveness on Monday 10th March in Valencia Ballroom D I will be presenting on Evidence based care of #psoriasis alongside great speakers @DrScottElman @DrShasaHu @AMostaghimi @AADmember

020

Zenas Yiu @zznyiu.bsky.social · 14/11/2024

Delighted to represent the British Association of Dermatologists in receiving the ILDS 2025 Young Dermatologists International Achievement Award for Europe Hope our guidelines work can benefit people with skin diseases seeking care globally #Dermatology www.ilds.org/news-ev...

ilds.org

Announcing the winners of the ILDS 2025 Young Dermatologists International Achievement Awards - ILDS

We are delighted to announce the recipients of the ILDS 2025 Young Dermatologist International Achievement Awards

030

Zenas Yiu @zznyiu.bsky.social · 23/10/2024

Here is the second part of the invited 2-part blog I wrote for the British Association of Dermatologists: Now you have asked a clinical question, what are the available tools you can use to answer it? #trials #observational_studies #registry www.bad.org.uk/how-t...

bad.org.uk

British Association of Dermatologists

Professional membership body for dermatologists in the UK and abroad.

000

Zenas Yiu @zznyiu.bsky.social · 27/09/2024

Great to see a head to head trial in #atopicdermatitis comparing #upadacitinib to #dupilumab showing superiority for the JAKi approach - reassuring safely profile suggests a healthy population in this trial. #EADVCongress

000

Zenas Yiu @zznyiu.bsky.social · 27/09/2024

Good safely profile for OX40 ligand blocker #amlitelimab for #atopicdermatitis in a phase 2b 68 week study no increases in conjunctivitis or CV risk #EADVCongress

Zenas Yiu @zznyiu.bsky.social · 27/09/2024

Great talk to remind us about the need for vaccination to prevent infections in people with skin diseases #EADVCongress

000

Zenas Yiu @zznyiu.bsky.social · 26/09/2024

Imsidolimab promising second agent for the treatment of #GPP #EADVCongress

000

Zenas Yiu @zznyiu.bsky.social · 26/09/2024

Great session this morning on #hidradenitis @ #EADVCongress on pathogenesis, comorbidities, guidelines, and more!

000

Zenas Yiu @zznyiu.bsky.social · 26/09/2024

Great session this morning on #hidradenitis @ #EADVCongress on pathogenesis, comorbidities, guidelines, and more!

000

Disease modification not well defined as yet for #psoriasis - some hypothetical suggested MOAs include reduction of TRM T cells #EADVCongress

000

Very high placebo response, as with other trials, for #Izokibep trials for #hidradenitis. Response rate looks similar to other IL-17s despite novel MOA #EADVCongress #EADV2024

000

Great talk by Zoe Venables on identifying high risk groups in skin cancer #EADVCongress #EADV2024

000

Very nice and robust study from BioDay registry - JAKi > biologics for infection risk in #atopiceczema #EADVCongress

000

Important area looking at best next treatment for people suffering from dupilumab induced eye or facial symptoms Some important limitations but helpful and suggestive of JAKi as best next modality #EADVCongress

000

Great job by Mike Ardern Jones presenting some complex data from A-STAR on PROMs and EASI Population correlation weak -individual correlation better

000

Interesting data from phenotypic switch from #psoriasis and #eczema and vice versa #EADVCongress #EADV2024

000